A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806) Article

Alexander, Brian M, Wang, Meihua, Yung, WK Alfred et al. (2013). A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806) . JOURNAL OF NEURO-ONCOLOGY, 111(1), 33-39. 10.1007/s11060-012-0987-0

cited authors

  • Alexander, Brian M; Wang, Meihua; Yung, WK Alfred; Fine, Howard A; Donahue, Bernadine A; Tremont, Ivo W; Richards, Ray S; Kerlin, Kevin J; Hartford, Alan C; Curran, Walter J; Mehta, Minesh P

sustainable development goals

authors

publication date

  • January 1, 2013

published in

keywords

  • ADULTS
  • AGENT
  • Angiogenesis inhibitor
  • Clinical Neurology
  • Clinical trial
  • Controlled
  • ENDOTHELIAL GROWTH-FACTOR
  • EXPRESSION
  • GLIOMAS
  • Glioblastoma
  • IRINOTECAN
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Radiation therapy
  • Science & Technology
  • TEMOZOLOMIDE
  • TRIAL DESIGN
  • Thalidomide

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 33

end page

  • 39

volume

  • 111

issue

  • 1